{"entity":{"id":"nct07452224","kind":"trial","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by iLeukon Therapeutics, Inc., now recruiting.","summary":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07452224 by iLeukon Therapeutics, Inc., with 80 participants planned, started 2026-06-29 and due to reach its primary completion in 2029-06. Interventions recorded: ILKN421H, Pembrolizumab. Conditions listed: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07452224","url":"https://clinicaltrials.gov/study/NCT07452224"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07452224","phase":"2","setting":"An Open-Label Phase II Study of ILKN421H in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","sponsor":"iLeukon Therapeutics, Inc.","enrolled":80,"outcomes":[]},"route":"/trials/nct07452224/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}